Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
97 hedge funds and large institutions have $147M invested in Sorrento Therapeutics, Inc. in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 22 reducing their positions, and 15 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 22
20% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 15
3% more funds holding
Funds holding: 94 → 97 (+3)
30% less capital invested
Capital invested by funds: $209M → $147M (-$62.1M)
88% less call options, than puts
Call options by funds: $249K | Put options by funds: $2M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.92M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$7.58M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.13M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.01M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$2.54M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$1.54M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.52M |
| 4 |
Renaissance Technologies
New York
|
-$1.42M |
| 5 |
Millennium Management
New York
|
-$1.36M |
SRNE Hedge Fund Activity: Q3 2018 in Review
97 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q3 2018, worth a combined $147M — down 30% from $209M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new SRNE positions and 15 closed out — a net gain of 3 holders — while 29 added to existing stakes and 22 trimmed.
The largest buyer was BlackRock, adding an estimated $7.92M. The largest seller was Wells Fargo, cutting an estimated $2.54M.
- 97 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q3 2018, up from 94 in Q2 2018.
- Funds reported $147M of Sorrento Therapeutics, Inc. stock for Q3 2018, down 30% quarter-over-quarter.
- 18 funds opened new Sorrento Therapeutics, Inc. positions in Q3 2018 and 15 closed out, a net change of +3 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q3 2018 was BlackRock, an estimated $7.92M added.
- The largest Sorrento Therapeutics, Inc. seller in Q3 2018 was Wells Fargo, an estimated $2.54M sold.
Based on aggregated 13F filings for Q3 2018.